Table 1.
Clinical characteristics of cohort at baseline.
| CLL (n = 17) | MBL (n = 13) | Total (n = 30) | |
|---|---|---|---|
| Age in years | |||
| Median (range) | 69.0 (49.0–80.0) | 73.0 (60.0–82.0) | 69.5 (49.0–82.0) |
| Female | 7 (41.2%) | 4 (30.8%) | 11 (36.7%) |
| Race, White | 17 (100%) | 13 (100%) | 30 (100%) |
| Ethnicity, Not Hispanic or Latino | 17 (100%) | 13 (100%) | 30 (100%) |
| Years from Diagnosis to Study Entry | |||
| Median (range) | 5.0 (0.1–10.6) | 5.8 (0.6–14.8) | 5.4 (0.1–14.8) |
| Rai Stage for CLL | |||
| 0 | 10 (58.8%) | n/a | n/a |
| 1 | 2 (11.8%) | ||
| 2 | 2 (11.8%) | ||
| 3 | 2 (11.8%) | ||
| 4 | 1 (5.9%) | ||
| IGHV mutation | |||
| Missing data | 3 | 3 | 6 |
| Mutation | 10 (71.4%) | 7 (70.0%) | 17 (70.8%) |
| Unmutated | 4 (28.6%) | 3 (30.0%) | 7 (29.2%) |
| CD38 expression ≥ 30% | |||
| Missing data | 0 | 2 | 2 |
| No (CD38 negative) | 15 (88.2%) | 9 (81.8%) | 24 (85.7%) |
| Yes (CD38 positive) | 2 (11.8%) | 2 (18.2%) | 4 (14.3%) |
| FISH | |||
| Missing data | 2 | 2 | 4 |
| Normal | 7 (46.7%) | 3 (27.3%) | 10 (38.5%) |
| 13q- | 5 (33.3%) | 6 (54.5%) | 11 (42.3%) |
| Trisomy 12 | 3 (20.0%) | 1 (9.1%) | 4 (15.4%) |
| 11q- | 0 | 1 (9.1%) | 1 (3.9%) |
| 17p- | 0 | 0 | 0 |
| Days from baseline immunogenicity labs (pre-vaccine) to follow-up immunogenicity labs (post vaccine) | |||
| Median (IQR) | 30.0 (28.0, 33.0) | 27.0 (25.0, 30.0) | 28.5 (26.0, 31.8) |
CLL = chronic lymphocytic leukemia.
MBL = monoclonal B cell lymphocytosis.
IGHV = immunoglobulin heavy chain gene.
FISH = Fluorescence in situ hybridization.
IQR = interquartile range.